Your browser doesn't support javascript.
loading
Pregnancy, fertility concerns and fertility preservation procedures in a national study of French breast cancer survivors.
Mangiardi-Veltin, Manon; Sebbag, Clara; Rousset-Jablonski, Christine; Ray-Coquard, Isabelle; Berkach, Clémentine; Laot, Lucie; Wang, Yuting; Abdennebi, Inès; Labrosse, Julie; Sautter, Camille; Toussaint, Aullène; Sablone, Laura; Laas, Enora; Khallouch, Sarah; Coussy, Florence; Santulli, Pietro; Chapron, Charles; Bobrie, Angelique; Jacot, William; Sella, Nadir; Dumas, Elise; Sénéchal-Davin, Claire; Espie, Marc; Giacchetti, Sylvie; Maitrot, Lorraine; Plu-Bureau, Geneviève; Coutant, Charles; Guerin, Julien; Asselain, Bernard; Fumoleau, Pierre; Rodrigues, Manuel; Decanter, Christine; Mailliez, Audrey; Delrieu, Lidia; Lemoine, Amélie; Jouannaud, Christelle; Houdre, Doriane; Reyal, Fabien; Hamy, Anne-Sophie.
Afiliación
  • Mangiardi-Veltin M; Department of Medical Oncology, Institut Curie, Paris, France, University Paris, Paris, France.
  • Sebbag C; Department of Surgical Oncology, Institut Curie, Paris, France, University Paris, Paris, France.
  • Rousset-Jablonski C; Centre Léon Bérard, Lyon, France, RESearch on HealthcAre PErformance (RESHAPE), University Claude Bernard Lyon 1, Lyon, France.
  • Ray-Coquard I; Centre Léon Bérard, Lyon, France, RESearch on HealthcAre PErformance (RESHAPE), University Claude Bernard Lyon 1, Lyon, France.
  • Berkach C; Department of Surgical Oncology, Institut Curie, Paris, France, University Paris, Paris, France.
  • Laot L; Department of Surgical Oncology, Institut Curie, Paris, France, University Paris, Paris, France.
  • Wang Y; Department of Medical Oncology, Institut Curie, Paris, France, University Paris, Paris, France.
  • Abdennebi I; Department of Surgical Oncology, Institut Curie, Paris, France, University Paris, Paris, France.
  • Labrosse J; Department of Surgical Oncology, Institut Curie, Paris, France, University Paris, Paris, France.
  • Sautter C; Department of Surgical Oncology, Institut Curie, Paris, France, University Paris, Paris, France.
  • Toussaint A; Department of Surgical Oncology, Institut Curie, Paris, France, University Paris, Paris, France.
  • Sablone L; Department of Surgical Oncology, Institut Curie, Paris, France, University Paris, Paris, France.
  • Laas E; Department of Surgical Oncology, Institut Curie, Paris, France, University Paris, Paris, France.
  • Khallouch S; Department of Surgical Oncology, Institut Curie, Paris, France, University Paris, Paris, France.
  • Coussy F; Department of Medical Oncology, Institut Curie, Paris, France, University Paris, Paris, France.
  • Santulli P; Department of Obstetrics and Gynecology, Hôpital Cochin, Paris, France, University Paris, Paris, France.
  • Chapron C; Department of Obstetrics and Gynecology, Hôpital Cochin, Paris, France, University Paris, Paris, France.
  • Bobrie A; Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.
  • Jacot W; Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France.
  • Sella N; Residual Tumor and Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, Paris, France.
  • Dumas E; Residual Tumor and Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, Paris, France.
  • Sénéchal-Davin C; Department of Oncogenetics, Institut Bergonié, Bordeaux, France.
  • Espie M; Sénopole, Hôpital Saint-Louis, AP-HP, Paris, France, University Paris, Paris, France.
  • Giacchetti S; Sénopole, Hôpital Saint-Louis, AP-HP, Paris, France, University Paris, Paris, France.
  • Maitrot L; Department of Obstetrics and Gynecology, Hôpital Cochin, Paris, France, University Paris, Paris, France.
  • Plu-Bureau G; Department of Obstetrics and Gynecology, Hôpital Cochin, Paris, France, University Paris, Paris, France.
  • Coutant C; Department of Surgical Oncology, Centre Georges-François Leclerc (Unicancer), Dijon, France.
  • Guerin J; Data Factory, Data Office, Institut Curie, 25 Rue d'Ulm, Paris 75005, France.
  • Asselain B; Department of Biostatistics, Institut Curie, Paris, France.
  • Fumoleau P; Department of Medical Oncology, Institut Curie, Paris, France, University Paris, Paris, France.
  • Rodrigues M; Department of Medical Oncology, Institut Curie, Paris, France, University Paris, Paris, France.
  • Decanter C; ART Department, Centre Hospitalier Régional Lille, Lille, France.
  • Mailliez A; Department of Medical Oncology, Centre Oscar Lambert, Lille, France.
  • Delrieu L; Residual Tumor and Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, Paris, France.
  • Lemoine A; Department of Medical Oncology, Institut Jean Godinot, Reims, France.
  • Jouannaud C; Department of Medical Oncology, Institut Jean Godinot, Reims, France.
  • Houdre D; Residual Tumor and Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, Paris, France.
  • Reyal F; Department of Surgical Oncology, Institut Curie, Paris, France, University Paris, Paris, France; Residual Tumor and Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U932 Immunity and Cancer, University Paris, Paris, France; Clinical Research Department, Centre Geo
  • Hamy AS; Department of Medical Oncology, Institut Curie, Paris, France, University Paris, Paris, France; Department of Surgical Oncology, Institut Curie, Paris, France, University Paris, Paris, France; Residual Tumor and Response to Treatment Laboratory, RT2Lab, Translational Research Department, INSERM, U93
Reprod Biomed Online ; 44(6): 1031-1044, 2022 06.
Article en En | MEDLINE | ID: mdl-35525718
ABSTRACT
RESEARCH QUESTION What are the real-life oncofertility practices in young women diagnosed with breast cancer?

DESIGN:

The FEERIC (FErtility, prEgnancy, contRaceptIon after breast Cancer in France) study is a web-based cohort study launched with the French collaborative research platform Seintinelles. The current work is based on the enrolment self-administered questionnaire of 517 patients with prior breast cancer diagnosis, free from relapse and aged 18 to 43 years at inclusion (from 12 March 2018 to 27 June 2019).

RESULTS:

Median age at breast cancer diagnosis was 33.6 years and 424 patients (82.0%) received chemotherapy. Overall, 236 (45.6%) patients were offered specialized oncofertility counselling, 181 patients underwent at least one fertility preservation procedure (FPP); 125 (24.2%) underwent one or more FPP with material preservation (oocytes n = 108, 20.9%; embryos n = 31, 6.0%; ovarian cryopreservation n = 6, 1.2%) and 78 patients received gonadotrophin-releasing hormone agonists (15.1%). With a median follow-up of 26.9 months after the end of treatments, 133 pregnancies had occurred in 85 patients (16.4%), including 20 unplanned pregnancies (15.0%). Most of the pregnancies were natural conceptions (n = 113, 87.6%), while 16 (12.4%) required medical interventions. For the planned pregnancies, median time to the occurrence of an ongoing pregnancy was 3 months. Patients who had an unplanned pregnancy reported lower rates of information on the consequences of the treatments on fertility (P = 0.036) at diagnosis.

CONCLUSIONS:

Most of the patients were not offered proper specialized oncofertility counselling at the time of breast cancer diagnosis. Naturally conceived pregnancies after breast cancer were much more frequent than pregnancies resulting from the use of cryopreserved gametes. Adequate contraceptive counselling seems as important as information about fertility and might prevent unplanned pregnancies.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Preservación de la Fertilidad / Supervivientes de Cáncer Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Female / Humans / Pregnancy Idioma: En Revista: Reprod Biomed Online Asunto de la revista: MEDICINA REPRODUTIVA Año: 2022 Tipo del documento: Article País de afiliación: Francia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Preservación de la Fertilidad / Supervivientes de Cáncer Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Límite: Female / Humans / Pregnancy Idioma: En Revista: Reprod Biomed Online Asunto de la revista: MEDICINA REPRODUTIVA Año: 2022 Tipo del documento: Article País de afiliación: Francia
...